Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment

HIV Medicine

Volumn 3, Issue 1, 2002, Pages 49-55

  Mauss, S ^g   Corzillius, M ^a   Wolf, E ^b   Schwenk, A ^c   Adam, A ^d   Jaeger, H ^b   Knechten, H ^e   Goelz, J ^f   Goetzenich, A ^d  

^a UNIVERSITY OF KIEL   (Germany)

^b HIV Practice Centre Karlsplatz   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d HIV Practice Centre   (Germany)

^e German Org representing Phys in Private Prac caring HIV infected ind (DAGNAE)   (Germany)

^f Practice Centre Kaiserdamm   (Germany)

^g NONE

Author keywords

Antiretroviral therapy; HIV; HIVLD

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; AGED; AIDS RELATED COMPLEX; ANTHROPOMETRIC PARAMETERS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DAILY LIFE ACTIVITY; FACE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIMB; LIPID STORAGE; LIPODYSTROPHY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PRIVATE PRACTICE; PROSPECTIVE STUDY; QUALITY OF LIFE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SELF ESTEEM; SENSITIVITY AND SPECIFICITY; SEXUALITY; SOCIAL ASPECT; TEACHING HOSPITAL; VISUAL ANALOG SCALE;

ADULT; AGED; ANTHROPOMETRY; ANTI-HIV AGENTS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; GERMANY; HIV INFECTIONS; HUMANS; LIPODYSTROPHY; LOGISTIC MODELS; MALE; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; QUALITY OF LIFE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; ROC CURVE; STAVUDINE;

EID: 0036190733     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-2662.2001.00100.x     Document Type: Article

References (29)

1. A syndrome of peripheral lipodystrophy and insulin resistance due to HIV protease inhibitors
2. Epidemiological and clinical aspects of the metabolic complications of HIV infection: The fat redistribution syndrome
3. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
4. Fat distribution and metabolic changes in patients with HIV infection
5. (Please give title of presentation.)
6. HAART is not hard enough: Virological failure after 12 months of treatment in antiretroviral therapy-naive HIV+ patients
7. Use and interpretation of anthropometric indicators of nutritional status
8. Lipodystrophic syndromes in a cohort of HIV-1-infected patients receiving HA antiretroviral therapy with a protease inhibitor
9. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
10. Metabolic changes in HIV-infected patients treated with protease inhibitors
11. Associated lipodystrophy metabolic disorders due to protease inhibitor containing regimen
12. Indinavir-associated lipodystrophy
13. Prevalence of metabolic complications in a large diverse cohort of HIV-infected persons
14. Prevalence of lipodystrophy in the long-term follow-up of a clinical trial comparing various combinations of nucleoside reverse transcriptase inhibitors, ALBI trial (ANRS 070)
15. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
16. A syndrome of peripheral fat wasting (lipodystropy) in patients receiving long-term nucleoside analogue therapy
17. Lipodystrophy related to NRT inhibitors in HAART
18. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-related lipodystrophy
19. A syndrome of lipodystrophy (LD), lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue reverse transcriptase inhibitor therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
20. Lack of clinical lipodystrophy in patients receiving efavirenz+ NRTIs in study 006
21. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advanced AIDS-related complex
22. Endocrine and metabolic disturbance in human immunodeficiency virus infection and the acquired immune deficiency syndrome
23. Cytokines and chemokines in HIV-infections: Implications for therapy
24. Lipodystrophy, glucose and lipid metabolism dysfunctions. Aquitaine Cohort, 1999
25. Impaired glucose tolerance, beta-cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
26. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects
27. Pathogenesis of HIV-1-protease inhibitor associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
28. Alterations in body fat distribution in HIV-infected men and women